Antibacterial class is not obviously important in outpatient pneumonia: A meta-analysis

European Respiratory Journal

Volumn 31, Issue 5, 2008, Pages 1068-1076

  Maimon, N ^a   Nopmaneejumruslers, C ^b   Marras, T K ^c,d  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MOUNT SINAI HOSPITAL   (Canada)

^d TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Antibiotic; Community acquired pneumonia; Outpatient; Treatment

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFACLOR; CEFDITOREN; CEFIXIME; CEFUROXIME; CEPHALOSPORIN; CLARITHROMYCIN; GREPAFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SPARFLOXACIN; TROVAFLOXACIN; QUINOLONE DERIVATIVE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG EFFECT; HOSPITALIZATION; HUMAN; META ANALYSIS; OUTPATIENT; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CLASSIFICATION; COMMUNICABLE DISEASE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FLUOROQUINOLONES; HUMANS; MACROLIDES; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 47049124628     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00109007     Document Type: Article

References (24)

1. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-837.
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72.
3. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56: Suppl. 4, iv1-iv58.
4. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383-421.
5. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one-year prospective study of 346 consecutive patients. Thorax 1996; 51: 179-184.
6. Bjerre LM, Verheij TJM, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev 2004; 2: CD002109.
7. Mills GD, Oehley MR, Arrol B. Effectiveness of β lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005; 330: 456-460.
8. Heintjes E, Berger MY, Bierma-Zeinstra SMA, Bernsen RMD, Verhaar JAN. Exercise therapy for patellofemoral pain syndrome. Cochrane Database Syst Rev 2002; 4: CD003472.
9. Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002; 24: 736-751.
10. Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther 2002; 24: 1854-1870.
11. Donowitz GR, Brandon ML, Salisbury JI, et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clin Ther 1997; 19: 936-953.
12. Hoeffken G, Meyer HP, Winter J, Verhoef L. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001; 95: 553-564.
13. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001; 119: 185-195.
14. O'Doherty B, Dutchman D, Pettit R, Maroli A. Randomised double-blind comparative study of grepafloxacin and amoxicillin in the treatment of patients with community-acquired pneumonia. Chemotherapy 1997; 40: 73-81.
15. Salvarezza CR, Mingrone H, Fachinelli H, Kijanczuk S. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. J Antimicrob Chemother 1998; 41: 75-80.
16. Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Microbiol Infect Dis 1991; 10: 872-877.
17. MacFarlane JT, Prewitt J, Gard P, Guion A. Comparison of amoxicillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections. Br J Gen Pract 1996; 46: 357-360.
18. Fogarty CM, Grossman C, Williams J, Haverstock D, Church D. Efficacy and safety of moxifloxacin versus clarithromycin for community-acquired pneumonia. Infect Med 1999; 16: 748-763.
19. Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther 1999; 21: 103-117.
20. Sokol WJ Jr, Sullivan JG, Acampora MD, Busman TA, Notario GF. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia. Clin Ther 2002; 24: 605-615.
21. Higuera F, Hidalgo H, Feris J, Giguere G, Collins JJ. Comparison of oral cefuroxime axetil and oral amoxycillin/ clavulanate in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996; 37: 555-564.
22. Fine M, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
23. Creer DD, Dilworth JP, Gillespie SH, et al. Aetiological role of viral and bacterial infections in acute adult lower respiratory infection (LRTI) in primary care. Thorax 2006; 61: 75-79.
24. Browner WS, Newman TB, Cummings SR, Hulley SB. Estimating sample size and power: the nitty gritty. In: Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman TB, eds. Designing Clinical Research. Philadelphia, Lippincott Williams & Wilkins, 2001; pp. 65-91.